Conducting Open Source Intelligence (OSINT), for wider intelligence, counter-terrorism and risk management work has become a complex and increasingly resource intensive task for both Government and Defence Intelligence agencies, and the commercial risk management sector alike. Social media monitoring offers a number of different methods to distribute results and analysis. The functionality of social media monitoring seamlessly integrates to su...

This two day event is designed to enhance SMis portfolio of pharmaceutical conferences, especially with a growing demand for biologic therapeutics. We ask the questions: What stimulates an immune response? How does the system cope with immunogenic compounds? And how do you screen for potential problems? The Conference will address all these concerns and enable Clinical Immunologists, Physicians and Specialists within the field of Immunogenicit...

Counterinsurgency writings implore armed forces to understand the Human Terrain (the population) in an insurgency. Key to this is an understanding how armed forces must operate, giving them the capability to promote their messages and values over to their adversaries in a global information environment that is connected, congested and contested. This method supports the entire spectrum of military operations – from early warning, rapid c...

Join SMi's Emergence of antimicrobial resistance in 2014 and how to stop it event on the 10 July in London, To understand the current thinking in antimicrobial chemotherapy and the global changesAntimicrobial resistance is perceived as an increasing threat to health and well-being globally. This is not a new message – it is one that has been repeated many times over the past three decades. What is new today and is the problem reaching a...

The launch event for Allergies is here and will be taking place on 9th July and 10th July 2014 in Central London. The market for Allergies is expected to reach $14.7 billion by 2015. As companies look to develop different compounds and antibodies to treat allergies, our 2014 event marks the path forward in terms of allergies within personalised medicines and beyond. The conference will examine advances in biology of biologic diseases; novel th...

This informative two day conference will give delegates the opportunity to hear the latest advancements in Big Data focusing on analytics for upstream exploration and production. Attendees will hear from a variety of industry expertise including operator case studies and leading big data vendors. In the last two years alone, Hadoop hit the big time, in-memory arrived, and practitioners saw data analysis deliver real results. This vast jump in...

Join SMi's Simulating Clinical Trials Using the FACTS Software Package event on the 9 July in London, to hear how simulation of clinical trials is used in the trial design process and how it benefits. Medical simulation is no longer an educational afterthought – it's a clinical learning necessity. Simulation adds considerable advantages to the clinical trial design process – using previous research data to its full potential, clari...

Over the next six years, the global mHealth market will continue to make a mark in a serious way, with the industry poised to exceed $49.1 billion by 2020, according to a new market report. According to research conducted by San Francisco-based market analysis and Grand View Research, monitoring services are projected to remain the dominant and most rapidly growing market segment, with revenue topping $1.2 billion in 2012, and seeing a nearly...

Join SMi's IP and the Generics Industry masterclass taking place on the 8 July in London, to navigate through the complicated landscape of intellectual property and generics.Intellectual Property (IP) lies at the very heart of the generics industry and it is vital to understand why the subject is so important. It represents the front line in the battles between originators , who want to protect their inventions for as long as possible, and the...

Since the European Paediatric Regulation was introduced in 2007, companies developing new medicinal products or new indications/routes of administration/pharmaceutical forms are obliged to present age-appropriate formulations for the paediatric population within a Paediatric Investigation Plan (PIP) to the European Medicines Agency. Paediatric drug development has become an essential part of drug development in general, it is a very complex ar...